Thyrotropin-releasing hormone has been reported to increase strength in patients 
with amyotrophic lateral sclerosis (ALS). DN-1417 is an analog of 
thyrotropin-releasing hormone, which has less endocrinologic activity, but more 
anterior horn cell stimulating effect (with no "autorefractory state"). However, 
2 mg DN-1417, IM twice a day for 1 month in an open-label trial, produced no 
objective improvement of strength in nine patients with ALS. No patient entered 
the double-blind, placebo-controlled phase of the trial.